FDA Approves First Medical Device for Obesity Treatment Targeting Brain-to-Stomach Signaling
Obesity SocietyThe United States Food and Drug Administration (FDA) approved EnteroMedic’s VBLOC® vagal blocking therapy, delivered via the Maestro® System, which is the first medical device approved for obesity treatment that targets the nerve pathway between the brain and the stomach. The Obesity Society calls this a "a novel device that interrupts signals from the stomach to the brain that are believed to be involved with stomach emptying and feelings of fullness."